Scan Results
Daily timeframeSiemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States,. Valued at $38.10B, SHL.DE is a large-cap name in its sector. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies.
Market Cap
$38.10B
Beta
0.80
P/E (TTM)
18.01
P/E (Fwd)
13.48
EPS (TTM)
$1.89
EPS (Fwd)
$2.52
ROE
11.5%
ROA
4.1%
Cash
$1.91B
Total Debt
$15.32B
Free CF
$2.49B
52W Change
-25.7%
Annual Financials
Cash vs Debt
The company holds $1.91B in cash, though total debt stands at $15.32B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $2.49B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $18.00B (2021) to $22.36B (2024), reflecting a 24% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Siemens Healthineers AG's trajectory.